JOINT CLINICAL RESEARCH CENTRE
Kampala, Uganda
JCRC and Makerere University join a Canada-Uganda partnership to develop, manufacture and deliver an affordable HIV cure, with first-in-human studies planned in both countries.
KAMPALA, UGANDA, 24 October 2026 — The Joint Clinical Research Centre (JCRC) has welcomed the Government of Canada’s announcement of CAD 24 million in federal funding for IMMUNEQUITY, an international initiative to develop a cure for HIV that is affordable and accessible from the outset. The six-year award, made through the New Frontiers in Research Fund (NFRF) Transformation stream and announced on 23 October 2026, is led by Western University, with JCRC and Makerere University as Ugandan co-developers.
IMMUNEQUITY is built on a simple principle: design the cure and the means to deliver it at the same time, with Ugandan partners involved from the first day rather than years later. Where many medical breakthroughs reach Africa a generation after they are made, IMMUNEQUITY aims to develop, test and manufacture an HIV cure in Uganda and Canada together.
The programme pairs advanced immune therapies with “frugal biomedical innovation”, low-cost manufacturing, diagnostics and cold-chain technology engineered to meet international standards at a fraction of the usual cost. It inverts the usual innovation sequence, in which a therapy is discovered, optimised and only later asked whether it can scale. In IMMUNEQUITY, access is a design criterion from the start: the cure and the means to deliver it are engineered in parallel. The programme is expected to include first-in-human cure studies in both Uganda and Canada, to build biotherapeutic manufacturing capacity in Uganda, and to train a new generation of Ugandan and Canadian scientists.
A cure proven at home
“For Uganda, this is the chance to prove an HIV cure works at home, working alongside Canada rather than years behind it,” said Dr Cissy Kityo-Mutuluuza, Executive Director of JCRC and a co-principal investigator on IMMUNEQUITY. “What makes this support so transformative is that it embeds health equity directly into the scientific process from day one. We are not only pursuing an HIV cure; we are building the manufacturing, the diagnostics and the people in Uganda to deliver it.”
“This is about more than a cure; it is about health sovereignty,” she added. “For too long, breakthroughs have been made in one part of the world and reached Africa a generation later. We are not building a cure for communities. We are building it with them and setting a new blueprint for how therapies should be developed and delivered globally.”
What the programme will do in Uganda
- Test cure biotherapeutics on clinical samples from Ugandans living with HIV, tailored to the virus subtypes circulating in the region;
- Establish local good-manufacturing-practice (GMP) production of cure biotherapeutics at JCRC, building towards “Made in Africa” capacity;
- Develop and validate affordable, point-of-care tests for monitoring HIV, suited to clinics with limited resources;
- Prepare for first-in-human cure studies in Uganda, alongside parallel studies in Canada;
- Train Ugandan graduate students and early-career scientists in cure science, manufacturing and regulation.
The scientific approach combines a “kick and kill” strategy, a biotherapeutic agent to wake HIV hidden in the body, with immune therapies, including antibody-producing cells and engineered natural-killer (CAR-NK) cells, to clear it, all designed for low-cost production and delivery.
The award builds on a decade-long partnership between JCRC and Western University. In 2025, Western conferred an honorary Doctor of Science on Dr Kityo-Mutuluuza in recognition of that collaboration and of JCRC’s contribution to global HIV research.
About IMMUNEQUITY
IMMUNEQUITY (Transforming Global Access to Immune Therapies through Frugal Biomedical Innovation) is a six-year international research programme led by Western University in Canada, funded through the Government of Canada’s New Frontiers in Research Fund (NFRF) Transformation stream. It brings together researchers in Canada and Uganda to develop an HIV cure and, in parallel, the low-cost manufacturing, diagnostics and delivery systems needed to make that cure accessible in Africa and worldwide. Partners include Western University, the University of British Columbia, the University of Ottawa, Université de Montréal and the University of Manitoba in Canada; the Joint Clinical Research Centre and Makerere University in Uganda; and SHC Therapeutics.
About the Joint Clinical Research Centre (JCRC)
The Joint Clinical Research Centre is a Ugandan not-for-profit research institution established by the Ministry of Health, the Ministry of Defence and Makerere University College of Health Sciences. For over three decades JCRC has led clinical research and care in sub-Saharan Africa, pioneering antiretroviral therapy in the region, conducting some of the continent’s first HIV vaccine trials, and more recently establishing cell and gene therapy capability in Uganda. JCRC’s mission is to advance health through research, and to ensure that scientific breakthroughs reach the communities that need them most.
Media contact: JCRC Communications Office, David Muyomba, dmuyomba@jcrc.org.ug, 0703873149. Website: www.jcrc.org.ug